This article is more than 5 years old. Information may no longer be current.
VIDEO: Omega-3 fatty acid proves beneficial for women
Click Here to Manage Email Alerts
NEW ORLEANS — In this featured video, Lori Mosca, MD, MPH, PhD, discusses the results of a subgroup analysis of the ANCHOR trial, focusing exclusively on women, which was presented at the American Heart Association Scientific Sessions.
While the ANCHOR trial tested the efficacy of icosapent ethyl (Vascepa, Amarin), a prescription omega-3 fatty acid, in individuals randomly assigned 2 g of the drug, 4 g of the drug or placebo, this subgroup analysis studied women who were randomized to either 4 g or placebo.
The data show significant reductions in the primary efficacy outcome of triglyceride levels and beneficial effects on lipids, lipoproteins, atherogenic parameters and inflammatory markers in women, Mosca, professor of medicine emerita at Columbia University Medical Center and director of the American Heart Association Go Red for Women Strategically Focused Research Network Center at Columbia, said.
“I think this is important for physicians to know and again reiterates for us that women tend to benefit to a similar degree [as men] with lipid-lowering therapy,” Mosca said. “We've seen [it] in many studies now, and this adds new evidence that the effect is similar using a prescription form of EPA [eicosapentaenoic acid].”